Every benefit figure attached to tesamorelin comes from trials in one population: adults with HIV-associated lipodystrophy. That is the only use it is FDA-approved for, and the visceral fat it removes reaccumulates when the drug is stopped.
Tesamorelin has three benefits that were actually measured rather than asserted: it reduces visceral fat, it raises IGF-1, and it improves triglycerides. It is a GHRH analog, so it stimulates the pituitary to release its own growth hormone rather than supplying hormone directly. It is also FDA-approved for one narrow use, reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. Every number below was recorded in that population.
- Visceral adipose tissue fell about 15% versus placebo across the phase 3 program [2][3]
- IGF-1 rose roughly 81% over 26 weeks [2]
- Triglycerides improved and glucose stayed neutral over a full 52 weeks [3][5]
- Visceral fat reaccumulated once the drug was stopped [4]
- FDA approval covers HIV-associated lipodystrophy only. Any other use is off-label, and compounded peptides sold for those uses are not FDA-approved at all [1]
Visceral Fat Reduction Is the Approved Benefit
This is the effect tesamorelin was built around, and the data behind it is unusually large for a GHRH analog. In a randomized placebo-controlled trial of 412 patients over 26 weeks, visceral adipose tissue fell 15.2% on tesamorelin versus a 5.0% increase on placebo [2]. A pooled analysis of two phase 3 trials covering 806 patients found a 15.4% treatment effect at 26 weeks, extending to 17.5% at 52 weeks [3]. A separate 404-patient trial reported a 10.9% reduction at 6 months [4].
The effect is selective for visceral and abdominal fat, the deep fat around the organs, rather than subcutaneous fat. That selectivity is why it was pursued for lipodystrophy, where visceral accumulation is the clinical problem.
Tesamorelin carries an N-terminal modification that confers resistance to degradation by dipeptidyl peptidase-4 [6], the enzyme that clears native GHRH within minutes. The longer functional half-life is what let it drive the sustained IGF-1 elevation the fat-loss effect depends on.
IGF-1 Elevation and What It Signals
IGF-1 is the downstream marker that shows the GH axis is being driven, and tesamorelin moves it substantially. In the 412-patient trial, IGF-1 rose 81.0% on tesamorelin versus a 5.0% decrease on placebo [2]. That is a large, measurable response, and it is the mechanism the visceral fat and lipid changes run through.
A large IGF-1 rise is also the reason monitoring matters. The label directs clinicians to watch for IGF-1 elevations above the normal range and reassess therapy when they persist. A benefit driven by pushing IGF-1 up is also the thing that has to be kept inside a sane range.
Triglycerides Improve, Glucose Stays Neutral
Growth hormone opposes insulin, so any GH axis therapy raises a fair question about glucose. The tesamorelin answer over a full course is reassuring. Pooled phase 3 data found no clinically meaningful differences in glucose parameters between groups at weeks 26 and 52 [3], and reviews describe an early modest rise in HbA1c that was no longer evident by 52 weeks [5].
On the lipid side the movement is favorable. The same review of tesamorelin trials documents reductions in triglycerides among the metabolic and cardiovascular indices that improved [5]. So the metabolic profile over a year is a triglyceride benefit against glucose neutrality, not a trade of one for the other.
The Benefit That Does Not Persist
This is the honest limit on the whole list. When tesamorelin is stopped, visceral fat reaccumulates [4]. The drug suppresses a process rather than permanently resetting it. Anyone planning a fixed-length course should treat the gains as maintained only while the drug is continued.
What the Benefits Do Not Include
The trials say nothing about anti-aging, bodybuilding, or general weight loss, because tesamorelin was never studied for them. It was approved for HIV-associated lipodystrophy and priced as a specialty product. No head-to-head trial has compared it with sermorelin, so any claim that one is stronger is an inference across separate studies, not a measured result.
- Not approved or studied for age-related body composition, athletic performance, or cosmetic fat loss [1]
- Reduces visceral fat, not subcutaneous fat, and the visceral loss reverses on discontinuation [4]
- Prohibited in tested sport: growth hormone releasing factors are named on the 2026 WADA Prohibited List under S2.2.4 [8]
- Patients with diabetes or impaired fasting glucose should have glucose monitored in the first 3 months
If Your Goal Is Age-Related Decline
Most people asking about tesamorelin benefits are not treating HIV lipodystrophy. They are asking whether a GHRH analog can help age-related changes in body composition. For that goal the practical option is compounded sermorelin, the shorter GHRH fragment telehealth platforms actually prescribe. Its adult data is thinner, but IGF-1 rises within 2 weeks of correct nightly dosing [7], and the honest starting point is the same either way: a baseline IGF-1 and a 90-day retest.
Tesamorelin is locked to HIV-associated lipodystrophy, so for age-related GH decline the GHRH analog telehealth actually prescribes is compounded sermorelin. SystemLabs draws a baseline IGF-1 before prescribing, so the dose is set against your own number rather than a trial in a different population.
Frequently Asked Questions
What are the main benefits of tesamorelin?
Three, all measured in HIV-associated lipodystrophy trials: visceral fat reduction of about 15% versus placebo [2][3], an IGF-1 increase of roughly 81% over 26 weeks [2], and improved triglycerides with neutral glucose over 52 weeks [3][5]. It is FDA-approved only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1].
How much visceral fat does tesamorelin remove?
Results vary by trial. A 412-patient study found a 15.2% reduction versus a 5.0% increase on placebo at 26 weeks [2]. A pooled analysis of 806 patients found a 15.4% treatment effect at 26 weeks and 17.5% at 52 weeks [3]. A separate 404-patient trial reported 10.9% at 6 months [4]. The loss is specific to visceral fat, not subcutaneous fat.
Do the benefits of tesamorelin last after you stop?
No. Visceral fat reaccumulated after tesamorelin was discontinued in the trial data [4]. The drug suppresses visceral fat accumulation while it is being taken rather than resetting it permanently, so the benefit is maintained only during continued use.
Is tesamorelin approved for anti-aging or bodybuilding?
No. Tesamorelin is FDA-approved only for excess abdominal fat in HIV-infected adults with lipodystrophy [1]. It was never studied for anti-aging, athletic performance, or general weight loss. It is also named on the 2026 WADA Prohibited List under growth hormone releasing factors and is banned in tested sport at all times [8].
Does tesamorelin raise blood sugar?
Not meaningfully over a full course. Pooled phase 3 data found no clinically meaningful differences in glucose parameters at weeks 26 and 52 [3], and an early modest rise in HbA1c was no longer evident by 52 weeks [5]. Patients with diabetes or impaired fasting glucose should still have glucose monitored during the first 3 months.
Can I get tesamorelin benefits from sermorelin instead?
Partly, and the evidence base is different. Both are GHRH analogs, but tesamorelin has large phase 3 trials while sermorelin has a much smaller adult data set. Sermorelin raises IGF-1 within 2 weeks of correct dosing [7], and it is what telehealth platforms prescribe for age-related decline because tesamorelin is restricted to its HIV indication. Judge either one on a baseline IGF-1 and a 90-day retest.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy HIV/AIDS (Auckland), 2011. PMID: 22096409. https://pubmed.ncbi.nlm.nih.gov/22096409/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
